Walking Aid

October 2007
PN;Oct2007, Vol. 61 Issue 10, p67
Trade Publication
The article announces that Hanger Orthopedic Group Inc. has granted Teijin Pharma Ltd. with exclusive rights to develop and commercialize Innovative Neutronics Inc.'s (IN) initial product offering, the WalkAide, in Japan. The product was cleared by the U.S. Food and Drug Association in September 2005 and made available in the U.S. in May 2006. The WalkAide System technology employs functional electrical stimulation (FES) to fight against lower-limb neuromuscular paralysis.


Related Articles

  • Hanger Orthopedic Group Appoints President of Innovative Neurotronics.  // O&P Business News;3/15/2006, Vol. 15 Issue 6, p39 

    Reports on the appointment of Jeff Martin as president of Innovative Neurotronics Inc., a subsidiary of Hanger Orthopedic Group. Remarks from Hanger Orthopedic Group COO Thomas Kirk regarding the appointment of Martin; Work experiences of Martin prior to his appointment; Educational background...

  • Hanger Gains FDA Approval and Hires New Management Team.  // O&P Business News;5/15/2006, Vol. 15 Issue 10, p51 

    Reports on the clearance received by Hanger Orthopedic Group Inc. subsidiary Innovative Neurotronics Inc. from the U.S. Food and Drug Administration to treat patients with the WalkAide System. Features of the functional electrical stimulation product; Examples of the medical benefits of the...

  • The Exoskeleton Frontier. Arrowsmith, Ranica // Orthopedic Design & Technology;Jul/Aug2014, Vol. 10 Issue 5, p86 

    The article presents information on a new exoskeleton device in the U.S. for patients with lower-limb immobility, which was approved for the first time by the U.S. Food & Drug Administration (FDA) in June 2014. The device, called ReWalk, helps individuals with lower-limb disabilities but who...

  • Product Briefs.  // Medical Device Daily;3/22/2012, Vol. 16 Issue 56, p10 

    The article reports on U.S. medical technology providers that received approval and clearance from the Food and Drug Administration (FDA) including CareFusion for its Viking on Nicolet EDX electrodiagnostic system, Olympus for its Thunderbeat hand instruments and universal surgical platform and...

  • Suppliers, FDA shine spotlight on switches. Johnsen, Michael // Drug Store News;4/2/2012, Vol. 34 Issue 5, p34 

    The article reports on the drive for future switch potential by way of the pharmacist and/or health technology sparked from the meeting of the U.S. Food and Drug Administration (FDA).

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Apr2009, Vol. 8 Issue 4, p10 

    The article offers global news briefs related to the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Aastrom Biosciences Inc.'s Phase II Impact-DCM clinical trial. The European Commission has granted marketing authorization for Eli Lilly and...

  • UDI Update: Comment now on devices on accelerated compliance schedule.  // Healthcare Purchasing News;Jan2013, Vol. 37 Issue 1, p6 

    The article discusses a blog which Karen Conway, an editorial advisory board member for the journal "Healthcare Purchasing News" wrote about a ruling about unique device identifiers which was issued by the U.S. Food and Drug Administration.

  • Orthotic network taking small steps but making big gains. Pallarito, Karen // Modern Healthcare;5/06/96, Vol. 26 Issue 19, p88 

    Reports on the Hanger Orthopedic Group's mobilization of a national network through membership contracts with smaller providers. Launching of Hanger's Opnet, a national orthotic and prosthetic (O&P) network of providers in February 1996; Number of patient-care centers; Managed care contracts...

  • Hanger Orthopedic Group Inc. Relocates Corporate Headquarters to Austin, Texas. Calabro, Anthony // O&P Business News;Spring2010, Vol. 19 Issue 3, p32 

    The article announces that Hanger Orthopedic Group Inc. has moved its corporate offices from Bethesda, Maryland to Austin, Texas on January 12, 2010.

  • Medical Device Technology User Fees. Bailey, Pamela G. // Medical Device Technology;Sep2002, Vol. 13 Issue 7, p37 

    Examines the significance of medical technology user-fee agreement for the Food & Drug Administration (FDA) in the U.S. Requirements of the proposal to pay fees to the FDA; Implications of the user fees to support FDA's revolution of new products; Issues confronted by the FDA in obtaining...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics